REHOVOT, Israel, Nov. 6 /PRNewswire-FirstCall/ -- BioView Ltd., (TASE: BIOV) from Rehovot, Israel, and Transgenomic, Inc. of Omaha, Nebraska announced today that they have entered into an agreement allowing Transgenomic to distribute BioView’s family of Scanning and Analysis Workstations in selected Western European countries and Scandinavia. Transgenomic’s European sales and support organization will market, sell and service the instruments. BioView’s products include the Duet, Allegro and Accord automated workstations for the scanning and classification of cells via fluorescence in-situ hybridization (FISH) and brightlight microscopy. The results of the scan are reviewed on the BioView Solo offline workstation for the final report.
The BioView products are intended for in-vitro diagnostic use as an aiding tool to the pathologist in the detection, classification and counting of cells of interest based on color, intensity, size, pattern, and shape. The BioView products have applications for testing in hematological disorders, breast cancer studies for Her-2 neu gene amplification, bladder cancer screening and follow up using Vysis UroVysion(TM) Bladder Cancer Recurrence Kit and prenatal and postnatal genetic testing.
BioView’s automated scanning microscope and image analysis systems help laboratories provide highly reliable test results to physicians and patients quickly and cost-effectively and also are used in advanced research.
Dr. Opher Shapira, President and CEO of BioView Ltd., views this agreement as an opportunity for BioView to expand its market penetration in Europe in an efficient manner. According to Shapira, “Transgenomic has a reputation amongst its European customer base for providing superior service and support. Following our success in the U.S. market, we believe that this agreement with Transgenomic will help establish us in a similar manner in the Western European and Scandinavian countries covered by this agreement.”
Craig Tuttle, President and CEO of Transgenomic added, “We are very excited to add BioView’s world-leading imaging platforms to our cytogenetics portfolio of products. These sophisticated imaging systems will complement our HANABI Metaphase Chromosome Harvester and spreader products and further expand our sales and service reach into cytogenetics and pathology laboratories across Europe.”
About BioView Ltd.
Established in 2000, and led by an expert team of biologists, software engineers and physicists, BioView develops, manufactures and supplies cell imaging equipment, biological kits and software to medical institutes and universities. BioView is a publicly traded company on the Israeli Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions. For more information about the BioView technology, and press related issues, please contact info@bioview.co.il or visit our website at http://www.bioview.co.il.
About Transgenomic: A decade of discovery 1997 - 2007
Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, and Transgenomic Clinical Reference Laboratory and Genomic Research Services. Transgenomic Clinical Reference Laboratory and Genomic Research Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com.
CONTACT: Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5400, fax, +1-402-452-5461, investorrelations@transgenomic.com
Web site: http://www.transgenomic.com/
http://www.bioview.co.il/
